Novo advances next-gen amycretin program after promising weight-loss, blood sugar data (Reuters) - Nov 25, 2025 - "Novo's mid-stage trial, the first to test amycretin in type 2 diabetes patients, studied once-weekly subcutaneous and oral versions of the drug compared to placebo in 448 people inadequately controlled on metformin with or without an SGLT2 inhibitor, a common class of diabetes treatment...Amycretin helped patients lose up to 14.5% of their body weight over 36 weeks with weekly injections, far outperforming placebo. The oral version delivered weight loss of up to 10.1%...Amycretin showed statistically significant reductions in blood glucose levels, meeting the main goal of the study, with up to 89.1% of patients achieving HbA1c levels below 7%. Side-effects were mostly mild gastrointestinal issues, Novo said. It plans to start late-stage trials in 2026."
New trial • P2 data • Type 2 Diabetes Mellitus
|